Celcuity (CELC) vs Fortrea (FTRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fortrea (FTRE) has outperformed Celcuity (CELC) over the past year, gaining 120.8% versus a gain of 33.7%. Celcuity is the larger company by market cap ($3.15 billion vs $1.91 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | FTRE |
|---|---|---|
| Share price | $64.45 | $20.07 |
| Market cap | $3.15B | $1.91B |
| 1-day change | -2.02% | -2.38% |
| YTD return | -34.05% | +19.19% |
| 1-year return | +33.66% | +120.84% |
| 5-year return | +261.43% | — |
| Forward P/E | — | 17.53 |
| EPS (TTM) | $-4.31 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-177.04M | — |
| 52-week high | $151.02 | $23.51 |
| 52-week low | $45.03 | $8.55 |
| Distance from 52-week high | -57.32% | -14.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +143.46% | +3.79% |
| Average volume | 1.21M | 1.47M |
| Shares outstanding | 48.93M | 95.10M |
| Employees | 155 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTRE has outperformed CELC by 87.2 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
CELC vs FTRE FAQ
Which is bigger, Celcuity or Fortrea?
Celcuity (CELC) is larger, with a market capitalization of $3.15B compared with $1.91B for Fortrea (FTRE).
Which stock has performed better over the past year, CELC or FTRE?
FTRE returned +120.84% over the past 12 months, compared with +33.66% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Fortrea in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.